Selank
Also known as · TP-7 · tuftsin-derived heptapeptide anxiolytic (Institute of Molecular Genetics, Russia)
- EvidenceClinical
- CategoryNootropic
- Routeintranasal
- Half-lifen.a.
01 / Dosing schedule
Cited dosing
Selank has published human anxiety trial data from Russian groups, including a randomized comparison against medazepam, but no Western regulatory review. The dose reported in a European Psychiatry congress abstract is 2700 microg/day intranasally, with 900 microg as a single dose.
Selank in generalized anxiety disorder — intranasal
| Phase | Dose & frequency |
|---|---|
| Daily dose | 2700 microg/day intranasally |
| Single dose used for EEG assessment | 900 microg |
| Time to rapid response | days 1-3 in 40% of patients (rapid responders) |
| Time to response in conventional responders | day 14 |
| Total treatment duration | n.a. — not stated in the abstract |
| Comparator trial (Zozulia 2008) | selank (n=30) vs medazepam (n=32) in 62 patients with GAD and neurasthenia; Selank dose n.a. in that abstract |
Source indication · Generalized anxiety disorder (and neurasthenia) — Russian clinical trials
- Injection frequency
- Daily intranasal dosing; the 2700 microg/day figure is a daily total, and the split across instillations is not stated in the abstract.
- Injection sites
- Not an injection in the cited trials: Selank was administered intranasally. No anatomical injection site exists in the source material.
02 / Reconstitution
Reconstitution reference
The Russian trials used a prepared intranasal Selank solution; no reconstitution procedure is published in either cited source.
03 / Overview
Protocol overview
Selank is a synthetic heptapeptide built from the immunomodulatory tetrapeptide tuftsin with a Pro-Gly-Pro stabilising tail. It is described in the European Psychiatry abstract as approved (in Russia) for the treatment of generalized anxiety disorder; it has no FDA or EMA approval.
The dose that can actually be cited is 2700 microg/day intranasally, in a study of 20 patients aged 24-52 with DSM-IV generalized anxiety disorder. A single 900 microg dose was used for the EEG substudy. Forty percent of patients were classed as rapid responders within days 1-3; the remaining 60% reached clinically significant change by day 14.
The best-known controlled trial, Zozulia and colleagues in Zh Nevrol Psikhiatr 2008, randomised 62 patients with GAD and neurasthenia to selank (n=30) versus the benzodiazepine medazepam (n=32). The abstract does not state the Selank dose or route, so those cells are n.a. here.
No human half-life, no injection-site data and no Western pharmacokinetic study were found in the sources fetched for this page. Reported evidence is real but thin and almost entirely Russian-language; treat published doses as trial documentation rather than a protocol.
04 / References